Gritstone bio Statistics
Total Valuation
Gritstone bio has a market cap or net worth of $62.21 million. The enterprise value is $117.94 million.
| Market Cap | 62.21M |
| Enterprise Value | 117.94M |
Important Dates
The next estimated earnings date is Wednesday, August 7, 2024, after market close.
| Earnings Date | Aug 7, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Gritstone bio has 108.57 million shares outstanding. The number of shares has increased by 3.47% in one year.
| Shares Outstanding | 108.57M |
| Shares Change (YoY) | +3.47% |
| Shares Change (QoQ) | +0.83% |
| Owned by Insiders (%) | 2.08% |
| Owned by Institutions (%) | 43.69% |
| Float | 100.14M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 3.98 |
| Forward PS | 3.94 |
| PB Ratio | 4.46 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 7.54 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.00, with a Debt / Equity ratio of 7.40.
| Current Ratio | 2.00 |
| Quick Ratio | n/a |
| Debt / Equity | 7.40 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -31.27 |
Financial Efficiency
Return on equity (ROE) is -232.40% and return on invested capital (ROIC) is -123.36%.
| Return on Equity (ROE) | -232.40% |
| Return on Assets (ROA) | -80.00% |
| Return on Capital (ROIC) | -123.36% |
| Revenue Per Employee | $67,727 |
| Profits Per Employee | -$627,242 |
| Employee Count | 231 |
| Asset Turnover | 0.09 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -71.35% in the last 52 weeks. The beta is 0.59, so Gritstone bio's price volatility has been lower than the market average.
| Beta (5Y) | 0.59 |
| 52-Week Price Change | -71.35% |
| 50-Day Moving Average | 0.78 |
| 200-Day Moving Average | 1.67 |
| Relative Strength Index (RSI) | 28.01 |
| Average Volume (20 Days) | 1,679,203 |
Short Selling Information
The latest short interest is 11.07 million, so 10.20% of the outstanding shares have been sold short.
| Short Interest | 11.07M |
| Short Previous Month | 11.59M |
| Short % of Shares Out | 10.20% |
| Short % of Float | 11.05% |
| Short Ratio (days to cover) | 7.20 |
Income Statement
In the last 12 months, Gritstone bio had revenue of $15.65 million and -$144.89 million in losses. Loss per share was -$1.24.
| Revenue | 15.65M |
| Gross Profit | 15.65M |
| Operating Income | -144.64M |
| Pretax Income | -144.89M |
| Net Income | -144.89M |
| EBITDA | -117.74M |
| EBIT | -140.40M |
| Loss Per Share | -$1.24 |
Balance Sheet
The company has $47.55 million in cash and $103.28 million in debt, giving a net cash position of -$55.73 million or -$0.51 per share.
| Cash & Cash Equivalents | 47.55M |
| Total Debt | 103.28M |
| Net Cash | -55.73M |
| Net Cash Per Share | -$0.51 |
| Equity (Book Value) | 13.96M |
| Book Value Per Share | 0.13 |
| Working Capital | 25.98M |
Cash Flow
In the last 12 months, operating cash flow was -$115.13 million and capital expenditures -$3.15 million, giving a free cash flow of -$118.27 million.
| Operating Cash Flow | -115.13M |
| Capital Expenditures | -3.15M |
| Free Cash Flow | -118.27M |
| FCF Per Share | -$1.00 |
Margins
Gross margin is 100.00%, with operating and profit margins of -924.49% and -926.13%.
| Gross Margin | 100.00% |
| Operating Margin | -924.49% |
| Pretax Margin | -926.13% |
| Profit Margin | -926.13% |
| EBITDA Margin | -752.58% |
| EBIT Margin | -897.43% |
| FCF Margin | -755.98% |
Dividends & Yields
Gritstone bio does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -3.47% |
| Shareholder Yield | -3.47% |
| Earnings Yield | -232.91% |
| FCF Yield | -190.12% |
Analyst Forecast
The average price target for Gritstone bio is $4.75, which is 728.97% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $4.75 |
| Price Target Difference | 728.97% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 4 |
| Revenue Growth Forecast (5Y) | 62.55% |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Gritstone bio has an Altman Z-Score of -9.87 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -9.87 |
| Piotroski F-Score | 2 |